Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats

被引:141
作者
Xu, Lin [1 ,2 ]
Fagan, Susan C. [3 ]
Waller, Jennifer L.
Edwards, David [4 ]
Borlongan, Cesar V. [1 ,2 ]
Zheng, Jianqing [1 ]
Hill, William D. [5 ]
Feuerstein, Giora [6 ]
Hess, David C. [1 ,2 ]
机构
[1] Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA
[2] VA Med Ctr, Augusta, GA 30904 USA
[3] Univ Georgia, Sch Pharm, Augusta, GA 30912 USA
[4] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI 48202 USA
[5] Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA
[6] Merck Res Labs, Dept Cardiovasc Dis, West Point, PA 19486 USA
关键词
Amyotrophic Lateral Sclerosis; Minocycline; Acute Ischemic Stroke; Reduce Infarct Size; Neurological Score;
D O I
10.1186/1471-2377-4-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Minocycline, a semi-synthetic tetracycline antibiotic, is an effective neuroprotective agent in animal models of cerebral ischemia when given in high doses intraperitoneally. The aim of this study was to determine if minocycline was effective at reducing infarct size in a Temporary Middle Cerebral Artery Occlusion model (TMCAO) when given at lower intravenous (IV) doses that correspond to human clinical exposure regimens. Methods: Rats underwent 90 minutes of TMCAO. Minocycline or saline placebo was administered IV starting at 4, 5, or 6 hours post TMCAO. Infarct volume and neurofunctional tests were carried out at 24 hr after TMCAO using 2,3,5-triphenyltetrazolium chloride (TTC) brain staining and Neurological Score evaluation. Pharmacokinetic studies and hemodynamic monitoring were performed on minocycline-treated rats. Results: Minocycline at doses of 3 mg/kg and 10 mg/kg IV was effective at reducing infarct size when administered at 4 hours post TMCAO. At doses of 3 mg/kg, minocycline reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56%. Minocycline at a dose of 10 mg/kg significantly reduced infarct size at 5 hours by 40% and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction. There was a significant difference in neurological scores favoring minocycline in both the 3 mg/kg and 10 mg/kg doses at 4 hours and at the 10 mg/kg dose at 5 hours. Minocycline did not significantly affect hemodynamic and physiological variables. A 3 mg/kg IV dose of minocycline resulted in serum levels similar to that achieved in humans after a standard 200 mg dose. Conclusions: The neuroprotective action of minocycline at clinically suitable dosing regimens and at a therapeutic time window of at least 4-5 hours merits consideration of phase I trials in humans in view of developing this drug for treatment of stroke.
引用
收藏
页数:7
相关论文
共 20 条
[1]   Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury [J].
Arvin, KL ;
Han, BH ;
Du, YS ;
Lin, SZ ;
Paul, SM ;
Holtzman, DM .
ANNALS OF NEUROLOGY, 2002, 52 (01) :54-61
[2]   Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection [J].
Fagan, SC ;
Edwards, DJ ;
Borlongan, CV ;
Xu, L ;
Arora, A ;
Feuerstein, G ;
Hess, DC .
EXPERIMENTAL NEUROLOGY, 2004, 186 (02) :248-251
[3]   Mechanisms of disease: Apoptosis and caspases in neurodegenerative diseases [J].
Friedlander, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1365-1375
[4]   Trends in acute ischemic stroke trials through the 20th century [J].
Kidwell, CS ;
Liebeskind, DS ;
Starkman, S ;
Saver, JL .
STROKE, 2001, 32 (06) :1349-1359
[5]   Minocycline slows disease progression in a mouse model of arnyotrophic lateral sclerosis [J].
Kriz, J ;
Nguyen, MD ;
Julien, JP .
NEUROBIOLOGY OF DISEASE, 2002, 10 (03) :268-278
[6]   Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat [J].
Lee, SM ;
Yune, TY ;
Kim, SJ ;
Park, DW ;
Lee, YK ;
Kim, YC ;
Oh, YJ ;
Markelonis, GJ ;
Oh, TH .
JOURNAL OF NEUROTRAUMA, 2003, 20 (10) :1017-1027
[7]   High-performance liquid chromatographic assay for minocycline in human plasma and parotid saliva [J].
Orti, V ;
Audran, M ;
Gibert, P ;
Bougard, G ;
Bressolle, F .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2000, 738 (02) :357-365
[8]   Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinages [J].
Power, C ;
Henry, S ;
Del Bigio, MR ;
Larsen, PH ;
Corbett, D ;
Imai, Y ;
Yong, VW ;
Peeling, J .
ANNALS OF NEUROLOGY, 2003, 53 (06) :731-742
[9]   Neuroprotective agents for clinical trials in Parkinson's disease - A systematic assessment [J].
Ravina, BM ;
Fagan, SC ;
Hart, RG ;
Hovinga, CA ;
Murphy, DD ;
Dawson, TM ;
Marler, JR .
NEUROLOGY, 2003, 60 (08) :1234-1240
[10]   CLINICAL PHARMACOKINETICS OF DOXYCYCLINE AND MINOCYCLINE [J].
SAIVIN, S ;
HOUIN, G .
CLINICAL PHARMACOKINETICS, 1988, 15 (06) :355-366